BBIO vs MRNA
Head-to-Head Stock Analysis & Investment Rating
Last Updated: Oct 29, 2026
BBIO
MRNA
Investment Advisor Scores
MRNA
AI Analyst Insights
Detailed Metrics Comparison
| Metric | BBIO | MRNA | Winner |
|---|---|---|---|
|
Valuation
Lower P/E and PEG ratios suggest a stock may be undervalued relative to earnings and growth. Value investors prefer lower multiples. |
|||
| Forward P/E | 0 | 23.0415 | Tie |
| PEG Ratio | 0 | 0 | Tie |
|
Growth
Higher revenue and earnings growth rates indicate a company is expanding faster. Strong growth often justifies premium valuations. |
|||
| Revenue Growth | 120.4% | 2.1% | BBIO |
| Earnings Growth | 0.0% | -85.1% | BBIO |
|
Quality & Profitability
Higher Tradestie Score and profit margins reveal how efficiently a company operates. Strong profitability indicates competitive advantages. |
|||
| Tradestie Score | 46.4/100 | 48.2/100 | MRNA |
| Profit Margin | -97.0% | -141.4% | BBIO |
|
Risk Profile
Lower Beta and Implied Volatility values indicate reduced market risk. Conservative investors favor stocks with less price volatility. |
|||
| Beta | 1.00 | 1.00 | Tie |
|
Sentiment
AI Recommendation reflects overall analyst and proprietary sentiment. Stronger recommendations signal higher conviction. |
|||
| AI Recommendation | HOLD | HOLD | Tie |
Relative Price Performance (Last 90 Days)
Current Technical Phase
BBIO
NeutralMixed signals - no dominant trend phase, RSI 65
MRNA
MarkupPrice above SMA50, rising 50-day trend (32.0% over 20 days), RSI 53
Fundamentals Snapshot
| Metric | BBIO | MRNA |
|---|---|---|
| Market Cap | — | — |
| Forward P/E | -286.0 | -53.3 |
| Trailing P/E | — | — |
| Revenue (TTM) | — | — |
| Revenue Growth | 1.9% | 0.3% |
| Gross Margin | 0.9% | -0.4% |
| Operating Margin | -0.4% | -0.8% |
| EPS | -3.07 | -6.98 |
| Dividend Yield | — | — |